Their specificity for TPO in targeting thyroid cancerous cell, their capacity to bind the C1q complement and their simultaneous recruitment of immune effector cells by binding to FcγR through their Fc region agree with the concept that they could be considered as potential tools for passive immunotherapy. The gene discussed is TPO; the disease is thyroid gland disorder.